Pfizer: A Case Study of the Market's Extremely Low Valuations [View article]
Generics typically chop off 80% off a branded drugs revenue base - market is smarter than all of us and pricing in Armageddon for Pfizer and that explains the ugly chart above. A low P/E means nothing in this market - PFE will only be bought by value long PMs if there is a tangible catalyst in the future for Pfizer - and sadly, there isn't one last time I checked. Add to this the threat from Obama that he wants the US govt to negotiate drug prices with Big Pharma on behalf of Medicare and viola - you land at PFEs battered share price. Likely washed out down here, but this is slow moving money for a while
-
Jan 01 20:57 pm
|Rating:
+1
0
All Comments by Dan Jacome »Pfizer: A Case Study of the Market's Extremely Low Valuations [View article]
Generics typically chop off 80% off a branded drugs revenue base - market is smarter than all of us and pricing in Armageddon for Pfizer and that explains the ugly chart above. A low P/E means nothing in this market - PFE will only be bought by value long PMs if there is a tangible catalyst in the future for Pfizer - and sadly, there isn't one last time I checked. Add to this the threat from Obama that he wants the US govt to negotiate drug prices with Big Pharma on behalf of Medicare and viola - you land at PFEs battered share price. Likely washed out down here, but this is slow moving money for a while